Author:
Zhong Jeffrey,Jang Albert,Garcia Jorge,Avril Norbert,Li Qiubai,Wojtylak Patrick,Shore Neal,Tagawa Scott,Barata Pedro
Reference161 articles.
1. Prospective genomic profiling of prostate cancer across disease states reveals germline and somatic alterations that may affect clinical decision making;Abida;JCO Precision Oncology,2017
2. AdvanCell Isotopes Pty Limited. (2023). TheraPb: Phase I/IIa dose escalation and toxicity study of [212Pb]Pb-ADVC001 in metastatic prostate adenocarcinoma (Clinical Trial Registration NCT05720130). clinicaltrials.gov. https://clinicaltrials.gov/study/NCT05720130.
3. The rise of PSMA ligands for diagnosis and therapy of prostate cancer;Afshar-Oromieh;Journal of Nuclear Medicine,2016
4. Repeated PSMA-targeting radioligand therapy of metastatic prostate cancer with 131I-MIP-1095;Afshar-Oromieh;European Journal of Nuclear Medicine and Molecular Imaging,2017
5. Developing the 134Ce and 134La pair as companion positron emission tomography diagnostic isotopes for 225Ac and 227Th radiotherapeutics;Bailey;Nature Chemistry,2021